Illumina Acquires Grail To Accelerate Patient Access To Life-Saving Multi-Cancer Early-Detection Test
Illumina Acquires Grail To Accelerate Patient Access To Life-Saving Multi-Cancer Early-Detection Test
08/19/21, 12:01 AM
Location
menlo parkIllumina, Inc. (NASDAQ: ILMN) announced today that it has acquired GRAIL, a healthcare company focused on life-saving early detection of multiple cancers, but will hold GRAIL as a separate company during the European Commission's ongoing regulatory review.
Company Info
Company info
Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as the global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit www.illumina.com and connect with us on Twitter, Facebook, LinkedIn, Instagram, and YouTube.
Investors:Brian Blanchett858.291.6421 IR@illumina.com
Media:Dr. Karen Birmingham646.355.2111 pr@illumina.com